Research Paper Volume 13, Issue 15 pp 19475—19485

FK506 binding protein 10: a key actor of collagen crosslinking in clear cell renal cell carcinoma

Immunohistochemistry analysis of FKBP10 and PLOD2 in ccRCC. Immunohistochemistry data of FKBP10 and PLOD2 in ccRCC samples and normal kidney tissues from the HPA database. (A) FKBP10 in normal kidney tissue. Antibody HPA057021, patient ID 1859. FKBP10 in glomeruli: staining not detected, weak intensity, quantityB) PLOD 2 in normal kidney tissue. Antibody CAB025898, patient ID 1933. PLOD2 in glomeruli: low staining, moderate intensity, quantity75%, membranous. (C) FKBP 10 in ccRCC tissue. Antibody HPA057021, patient ID 3039. FKBP10 in ccRCC tissue: high staining, strong intensity, quantity>75%, located in cytoplasmic/membranous. (D) PLOD2 in ccRCC tissue. Antibody CAB025898, patient ID 2564. PLOD2 in ccRCC tissue: high staining, strong intensity, quantity>75%, located in cytoplasmic/membranous.

Figure 2. Immunohistochemistry analysis of FKBP10 and PLOD2 in ccRCC. Immunohistochemistry data of FKBP10 and PLOD2 in ccRCC samples and normal kidney tissues from the HPA database. (A) FKBP10 in normal kidney tissue. Antibody HPA057021, patient ID 1859. FKBP10 in glomeruli: staining not detected, weak intensity, quantity<25%, located in cytoplasmic/membranous; FKBP10 tubules: low staining, weak intensity, quantity 25%-75%, membranous. (B) PLOD 2 in normal kidney tissue. Antibody CAB025898, patient ID 1933. PLOD2 in glomeruli: low staining, moderate intensity, quantity<25%, located in cytoplasmic membranous; PLOD2 tubules: medium staining, moderate intensity, quantity>75%, membranous. (C) FKBP 10 in ccRCC tissue. Antibody HPA057021, patient ID 3039. FKBP10 in ccRCC tissue: high staining, strong intensity, quantity>75%, located in cytoplasmic/membranous. (D) PLOD2 in ccRCC tissue. Antibody CAB025898, patient ID 2564. PLOD2 in ccRCC tissue: high staining, strong intensity, quantity>75%, located in cytoplasmic/membranous.